Levosalbutamol API Manufacturers

General Description:

Levosalbutamol, identified by CAS number 34391-04-3, is a notable compound with significant therapeutic applications. Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol).

Indications:

This drug is primarily indicated for: Indicated for the management of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Levosalbutamol undergoes metabolic processing primarily in: Pure (R)-salbutamol formulation known as levosalbutamol is metabolised up to 12 times faster than (S)-salbutamol by intestine. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Levosalbutamol are crucial for its therapeutic efficacy: Inhalation delivers the medication directly into the airways and lungs, thereby minimizing side effects because of reduced systemic absorption of the inhaled medications. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Levosalbutamol is an important consideration for its dosing schedule: 3.3 - 4 hours. This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Levosalbutamol exhibits a strong affinity for binding with plasma proteins: plasma protein binding is relatively low. This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Levosalbutamol from the body primarily occurs through: excreted into the urine. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Pharmacodynamics:

Levosalbutamol exerts its therapeutic effects through: It acts by relaxing smooth muscle in the bronchial tubes to increase air flow and relieve acute shortness of breath. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Levosalbutamol functions by: β2 adrenergic receptors on airway smooth muscle are Gs coupled and their activation by levosalbutamol leads to activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). Increased cyclic AMP activates protein kinase A which itself inhibits the phosphorylation of myosin produces lower intracellular ionic calcium concentrations, inducing muscle relaxation. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, potentially contributing to its benefit in asthma attacks. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Classification:

Levosalbutamol belongs to the class of organic compounds known as benzyl alcohols. These are organic compounds containing the phenylmethanol substructure, classified under the direct parent group Benzyl alcohols. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Benzyl alcohols subclass.

Categories:

Levosalbutamol is categorized under the following therapeutic classes: Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Agents to Treat Airway Disease, Alcohols, Amines, Amino Alcohols, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Ethanolamines, Ethylamines, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, Phenethylamines. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.